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Maxwell JT, Domeier TL, Blatter LA. Dantrolene prevents arrhythmogenic Ca 2ϩ release in heart failure. Am J Physiol Heart Circ Physiol 302: H953-H963, 2012. First published December 16, 2011 ; doi:10.1152/ajpheart.00936.2011.-In heart failure (HF), arrhythmogenic Ca 2ϩ release and chronic Ca 2ϩ depletion of the sarcoplasmic reticulum (SR) arise due to altered function of the ryanodine receptor (RyR) SR Ca 2ϩ -release channel. Dantrolene, a therapeutic agent used to treat malignant hyperthermia associated with mutations of the skeletal muscle type 1 RyR (RyR1), has recently been suggested to have effects on the cardiac type 2 RyR (RyR2). In this investigation, we tested the hypothesis that dantrolene exerts antiarrhythmic and inotropic effects on HF ventricular myocytes by examining multiple aspects of intracellular Ca 2ϩ handling. In normal rabbit myocytes, dantrolene (1 M) had no effect on SR Ca 2ϩ load, postrest decay of SR Ca 2ϩ content, the threshold for spontaneous Ca 2ϩ wave initiation (i.e., the SR Ca 2ϩ content at which spontaneous waves initiate) and Ca 2ϩ spark frequency. In cardiomyocytes from failing rabbit hearts, SR Ca 2ϩ load and the wave initiation threshold were decreased compared with normal myocytes, Ca 2ϩ spark frequency was increased, and the postrest decay was potentiated. Using a novel approach of measuring cytosolic and intra-SR Ca 2ϩ concentration (using the low-affinity Ca 2ϩ indicator fluo-5N entrapped within the SR), we showed that treatment of HF cardiomyocytes with dantrolene rescued postrest decay and increased the wave initiation threshold. Additionally, dantrolene decreased Ca 2ϩ spark frequency while increasing the SR Ca 2ϩ content in HF myocytes. These data suggest that dantrolene exerts antiarrhythmic effects and preserves inotropy in HF cardiomyocytes by decreasing the incidence of diastolic Ca 2ϩ sparks, increasing the intra-SR Ca 2ϩ threshold at which spontaneous Ca 2ϩ waves occur, and decreasing the loss of Ca 2ϩ from the SR. Furthermore, the observation that dantrolene reduces arrhythmogenicity while at the same time preserves inotropy suggests that dantrolene is a potentially useful drug in the treatment of arrhythmia associated with HF. arrhythmogenesis; calcium waves; excitation-contraction coupling; ryanodine receptor THE RYANODINE RECEPTOR (RyR) is an intracellular Ca 2ϩ release channel located on the sarcoplasmic reticulum (SR)/endoplasmic reticulum Ca 2ϩ store (42) . There are three known mammalian isoforms of the RyR (RyR1, RyR2, and RyR3), each with a distinct pattern of cellular and tissue expression and functional properties. RyR1 is the predominant isoform found in skeletal muscle (18) , whereas RyR2 is the most abundant in cardiac tissues (2) . RyRs respond to increased cytosolic Ca 2ϩ concentration ([Ca 2ϩ ] i ), leading to the release of Ca 2ϩ from intracellular stores in a process termed Ca 2ϩ -induced Ca 2ϩ release (CICR). The RyR channels have been well characterized at both the cellular and single channel levels, providing detailed insight into their biophysical and physiological properties (16, 19) . Numerous mutations of the RyR channel have been implicated in disease states, emphasizing its central role in regulating cellular Ca 2ϩ homeostasis (25, 27, 49) . The drug dantrolene is a skeletal muscle relaxant (15) that acts by stabilizing uncontrolled SR Ca 2ϩ release during excitation-contraction (E-C) coupling. E-C coupling describes the sequence of events where action potential (AP) depolarization of the cell membrane results in an increase in [Ca 2ϩ ] i , which activates Ca 2ϩ -sensitive contractile proteins in muscle cells. Dantrolene is a well-established treatment for malignant hyperthermia, a skeletal muscle condition associated with mutations of RyR1 (17) , where it has been used clinically at concentrations of ϳ10 M (27, 48) . Treatment with the drug suppresses the life-threatening symptoms of malignant hyperthermia (27) that are triggered by volatile anesthetics in susceptible patients. Dantrolene has been shown to bind to amino acids 590 -609 of RyR1, which presumably stabilizes the channel protein, thus providing evidence for a direct action of dantrolene on RyRs (32) . This stabilizing effect inhibits aberrant activation of the channel and prevents excessive Ca 2ϩ release from intracellular stores. Furthermore, dantrolene binds to the corresponding sequence (amino acids 601-620) of RyR2 (33, 47) and has recently been proposed to have effects on cardiac RyR2 (24, 50) ; however, no effect of the drug on the properties of native RyR2 channels has been observed in single channel analysis (12) . Recent evidence has suggested that dantrolene may ameliorate abnormal RyR2-mediated Ca 2ϩ release associated with heart failure (HF) (24, 31) . In HF (7), it has been hypothesized that interdomain interactions between the NH 2 -terminal and central domains of the RyR2 channel become destabilized or unzipped [possibly through posttranslational modifications such as phosphorylation (1, 30) or oxidation (44) ], thus contributing to channel dysfunction and altering cellular Ca 2ϩ -handling properties. Ca 2ϩ leak from the RyR during diastole increases, along with a higher propensity for RyR-mediated activation of potentially arrhythmogenic spontaneous Ca 2ϩ waves (13, 40) . Additionally, Ca 2ϩ leak through RyR2 contributes to the net loss of Ca 2ϩ from the cell as this Ca 2ϩ is subsequently extruded via Na ϩ /Ca 2ϩ exchanger (NCX) (37) . The loss of Ca 2ϩ from the cell decreases SR Ca 2ϩ content and subsequently weakens myocyte contraction as less Ca 2ϩ is available for beat-to-beat activation of the contractile proteins (26, 35) . Recent investigations have suggested that dantrolene may correct the abnormal RyR2-mediated Ca 2ϩ release associated with HF by stabilizing the interdomain interactions of RyR2 and preventing diastolic SR Ca 2ϩ release (23, 24, 31) .
In at room temperature (22-24°C) until indicator dye loading and subsequent experimentation. In addition, left ventricular myocytes were isolated from rabbits with nonischemic HF (n ϭ 5) induced by combined pressure and volume overload and characterized by the combination of gradual HF development (over 4 -9 mo, monitored by serial echocardiography), depressed systolic function, and arrhythmogenesis in an animal that has human-like Ca 2ϩ handling and elecrophysiological properties (36) . This model has been extensively studied and is well characterized at structural, biochemical, molecular, Ca 2ϩ -handling, and electrophysiological levels (11, 13, 36 -38, 40, 51) . All protocols were approved by the Institutional Animal Care and Use Committee. ]SR increases to levels where intra-SR fluo-5N is nearly saturated with Ca 2ϩ , and this therefore approximates maximal fluo-5N fluorescence (39) .
For all Ca 2ϩ concentration measurements, cells were placed on laminin-coated coverslips. APs and global Ca 2ϩ transients were elicited by electrical field stimulation using a pair of platinum electrodes (voltage set at ϳ50% above the threshold for contraction). Experiments were conducted at room temperature (22-24°C) .
Data analysis and statistics. Ca 2ϩ spark frequency [quantified as the number of sparks per second per 100 m of scanned distance: (sparks·s Ϫ1 ·(100 m) Ϫ1 )], amplitude, spatial width (full width at half-maximum and full width), duration (full duration at half-maximum and full duration), time to peak, maximum steepness of the upstroke, and decay kinetics were calculated using the SparkMaster algorithm (34) . Statistical comparisons were made using Student's t-test for paired or unpaired data, the nonparametric Mann-Whitney U-test for two samples, and the Wilcoxon signed-rank test for paired observations, with statistical significance set at P Ͻ 0.05. Data are presented as individual observations or as means Ϯ SE of n measurements, where n is the number of cells. ] i was significantly higher (normal myocytes: R ϭ 1.37 Ϯ 0.02, n ϭ 21; HF myocytes: R ϭ 1.65 Ϯ 0.03, n ϭ 13, P Ͻ 0.001); however, dantrolene had no effect on resting [Ca 2ϩ ] i , in either normal myocytes (R ϭ 1.35 Ϯ 0.02, n ϭ 16) or HF myocytes (R ϭ 1.64 Ϯ 0.03, n ϭ 12).
RESULTS

Effects of dantrolene on basal [
Cytosolic Ca 2ϩ transients elicited by field stimulation (1 Hz) were significantly reduced in amplitude (⌬R) in HF myocytes compared with normal cells (P Ͻ 0.002; Fig. 1) ; however, dantrolene treatment had no significant effect on the transient amplitude (Fig. 1C,a) . Furthermore, dantrolene had no effect on the kinetics of the Ca 2ϩ transient [normalized averaged Ca 2ϩ transients at an expanded timescale in the presence and absence of dantrolene are shown in Fig. 1 , A (normal myocytes) and B (HF myocytes), right].
To determine the effect of dantrolene on SR Ca 2ϩ load in both normal and HF myocytes, SR Ca 2ϩ was assessed by the application of 10 mM caffeine to empty the SR. The amplitude of the caffeine-induced cytosolic Ca 2ϩ transient (⌬R) served as a quantitative measure of SR Ca 2ϩ content. In normal myo-cytes (Fig. 1A) , dantrolene had no significant effect on SR Ca 2ϩ load (Fig. 1C,b) . However, in HF myocytes (Fig. 1B) , dantrolene significantly increased the SR Ca 2ϩ load (Fig.  1C,b) . Overall, in HF cardiomyocytes, the SR Ca 2ϩ load was significantly diminished compared with normal cells (P Ͻ 0.002). In both normal and HF myocytes, the effect of dantrolene on the Ca 2ϩ transient amplitude and SR Ca 2ϩ load at 0.5-Hz pacing was qualitatively the same as observed during 1-Hz pacing (data not shown).
Fractional release refers to the nonlinear relationship between SR Ca 2ϩ release and SR Ca 2ϩ load and serves as a quantitative measure for the efficiency of a given Ca 2ϩ trigger (L-type Ca 2ϩ current) to elicit CICR from the SR (3, 41). Fractional release was quantified as the AP-induced Ca 2ϩ transient amplitude (⌬R) divided by the amplitude of the caffeine-induced Ca 2ϩ transient. HF myocytes had significantly higher fractional release compared with normal myocytes (P Ͻ 0.05; Fig. 1C,c) , indicative of a compensatory mechanism to partially sustain SR Ca 2ϩ release and contractile strength in HF despite the decrease in SR Ca 2ϩ content (13, 20, 40) . Dantrolene had no effect on fractional release in normal myocytes. In HF myocytes, dantrolene caused a decrease in fractional release to levels near that observed in normal cells while not compromising inotropy (i.e., no significant change in the Ca 2ϩ transient amplitude). SR Ca 2ϩ content was also measured directly in cells during electrical stimulation (1 Hz) with a novel approach using the low-affinity Ca 2ϩ indicator fluo-5N entrapped within the SR Here and in the following figures, the placement of the solid horizontal bar for caffeine application indicates the point at which solutions were changed and includes a slight delay due to the time it takes for the solution to reach the myocyte. C: summary data of Ca 2ϩ transient amplitudes (a), SR Ca 2ϩ load (b), and fractional release (c). ⌬R, change in R; ⌬RTwitch/⌬RCaffeine; change in the R signal during twitch/during caffeine treatment. Normal: n ϭ 23; HF: n ϭ 13. *P Ͻ 0.005. (Fig. 2) 2C,a) while having no effect in normal myocytes, thus confirming the results obtained with indo-1 (Fig. 1) . Additionally, fractional release was determined from the fluo-5N measurements as the depletion amplitude (change in [Ca 2ϩ ] SR during a twitch) divided by diastolic SR Ca 2ϩ level. Fractional release was significantly increased in HF myocytes compared with control myocytes (P Ͻ 0.005), and dantrolene again decreased it near to levels seen in normal cells (Fig. 2C,b) , replicating the data obtained with indo-1 (Fig. 1) . The changes in SR load and fractional release in HF were consistent with previous data from our laboratory (13 Figure 3 shows example confocal line-scan images and corresponding local fluo-4 fluorescence profiles (⌬F/F 0 ) of Ca 2ϩ sparks from intact normal (A) and HF (B) myocytes under control conditions and after dantrolene application. Dantrolene had no effect on Ca 2ϩ spark frequency, amplitude, width, or duration in normal cells (Fig. 3C,a-d) . HF myocytes, however, exhibited a significantly increased spark frequency compared with normal cells (P Ͻ 0.001; Fig. 3D,a) previously published reports (13, 40, 51) . Treatment with dantrolene significantly decreased spark frequency in HF myocytes to values that were lower than normal myocytes and had no significant effect on the other spark parameters shown (Fig.  3D,b-d (Figs. 1C,b and 2C,a) .
Dantrolene inhibits postrest decay in HF myocytes. Postrest decay of SR Ca 2ϩ content is a phenomenon observed in rabbit . Here, we used the parameter of postrest decay of SR Ca 2ϩ content as a measure of SR Ca 2ϩ leak during rest. To assess the effects of dantrolene on postrest decay in normal and HF conditions, cells were field stimulated at 1 Hz, and SR Ca 2ϩ load was assessed by the application of 10 mM caffeine after 2 s and after 60 s of rest (protocol shown in Fig. 4A ). In normal myocytes (Fig. 4B) , the postrest decay of SR Ca 2ϩ content was minimal and the caffeine-induced Ca 2ϩ transient amplitude (⌬R) after 60 s of rest amounted to Ͼ90% of the amplitude observed immediately (2 s) after the cessation of pacing (Fig. 4D,a) . Dantrolene had no effect on the postrest decay in normal myocytes (Fig. 4, B and D,a) . In contrast, in HF myocytes, the postrest decay was significantly enhanced compared with control myocytes (P Ͻ 0.001; Fig. 4 ] SR was measured directly using fluo-5N. To quantify the postrest decay of [Ca 2ϩ ] SR with this approach, diastolic fluo-5N fluorescence during 1-Hz pacing was compared with remaining fluorescence after 60 s of rest (paired measurements). In normal myocytes (Fig. 5A) , the postrest decay of [Ca 2ϩ ] SR was small (Fig. 5C,a) and there was no significant change when control and dantrolene-treated cells were compared. In contrast, HF myocytes ] SR levels and the postrest decay of SR Ca 2ϩ content was accelerated. Dantrolene significantly slowed the postrest decay in HF myocytes (Fig.  5C,b) ] SR wave threshold in normal and failing myocytes. Spontaneous Ca 2ϩ waves were induced in normal and HF myocytes by incrementally (0.1-Hz steps) increasing pacing frequency in the presence of 7 mM extracellular Ca 2ϩ to facilitate loading of the SR. A period of pacing at a given frequency was followed by 10 s of rest, during which the occurrence of spontaneous Ca 2ϩ waves was monitored. As shown in the protocol shown in Fig. 6A , we determined with this approach, for each individual cell tested, the highest stimulation frequency that failed to result in Ca 2ϩ waves during the subsequent rest period and the lowest frequency at which a Ca 2ϩ wave could be elicited. In separate pacing trains, SR Ca 2ϩ content was measured at these respective frequencies using an application of 10 mM caffeine. In the example shown in Fig. 6A ,a, the myocyte was stimulated at 0.6 Hz, pacing was stopped, and no wave was observed in the ensuing rest period. Pacing was resumed at 0.7 Hz and then stopped, and a spontaneous Ca 2ϩ wave was observed during the rest period (Fig. 6A,b) . Subsequently, SR Ca 2ϩ loads were assessed by 10 mM caffeine application at these two pacing frequencies (Fig.  6, A,c and d) . Stimulation at 0.6 Hz resulted in a SR Ca 2ϩ load that was just below the threshold for wave initiation since no wave was observed during the rest period ( Fig. 6A,a; marked by the minus signs in Fig. 6B ), whereas at 0.7-Hz pacing, SR Ca 2ϩ content exceeded the Ca 2ϩ wave threshold and a wave was observed (Fig. 6A,b ; marked by the plus signs in Fig. 6B) . Using this protocol, as shown in Fig. 6A , the loads essentially bracketed the actual wave threshold (i.e., the exact SR Ca 2ϩ level where spontaneous waves occur). The experimental protocol was repeated in the absence and presence of dantrolene for both normal and HF myocytes. Our results show that HF myocytes had a significantly (P Ͻ 0.05) decreased wave threshold compared with normal cells (Fig. 6B, open bars in a  vs. b) . Dantrolene caused a significant increase of the wave threshold in HF myocytes (Fig. 6B,b) whereas in normal cells dantrolene had no effect (Fig. 6B,a) . This increase was sufficient to result in a significant decrease in propensity for spontaneous Ca 2ϩ waves. Consistent with a lack of effect of dantrolene on other parameters measured in normal cells (Figs.  1-5) , the drug did not alter the wave threshold in normal myocytes.
The wave threshold was also directly measured in terms of [Ca 2ϩ ] SR using fluo-5N entrapped in the SR. Myocytes were field stimulated at increasing frequencies, and the activation of spontaneous Ca 2ϩ waves upon the cessation of pacing was monitored for 10 s. The fluo-5N fluorescence traces shown in Fig. 7 include the last Ca 2ϩ depletion transients triggered by APs (solid triangles). Spontaneous Ca 2ϩ waves during the ensuing rest period are marked by filled circles in Fig. 7 . Figure  7A shows that dantrolene had no effect on the [Ca 2ϩ ] SR levels at which Ca 2ϩ waves occurred in normal cells (summarized in Fig. 7C,a) . In HF myocytes (Fig. 7B) , however, the wave threshold was decreased compared with normal myocytes (Fig.  7C ), but dantrolene significantly increased the wave threshold. Thus, dantrolene exerts antiarrhythmic effects in HF myocytes by increasing the SR Ca 2ϩ wave threshold.
DISCUSSION
In HF, profound disturbances in Ca 2ϩ signaling and E-C coupling lead to compromised contractility and an increased propensity of arrhythmia. In HF, the twitch Ca 2ϩ transient amplitude and SR Ca 2ϩ content are typically reduced (8, 35) due to a combination of enhanced diastolic Ca 2ϩ leak, lower sarco(endo)plasmic reticulum Ca 2ϩ -ATPase activity, diminished resequestration of Ca 2ϩ into the SR, and enhanced Ca 2ϩ extrusion from the cell via NCX (7, 13, 37, 40) . The hypothesis of increased diastolic SR Ca 2ϩ leak in HF was based on the observation of a higher RyR2 open probability measured in single channel lipid bilayer recordings (30) , which was later confirmed at the level of intact myocytes by several groups (1, 5, 40, 51 that is typical in HF, dantrolene was able to prevent potentially deleterious spontaneous arrhythmogenic Ca 2ϩ release and preserve cardiac inotropy presumably through the stabilization of RyR2 (23, 24) . It has been proposed that during the progression of HF, the RyR2 channel becomes excessively leaky due to defective interdomain interactions (also referred to as unzipping of the domains) (23) and that dantrolene can act on RyR2 by restabilizing these intramolecular interactions (24) . This model is consistent with our observation that dantrolene only had effects on Ca 2ϩ signaling in HF myocytes but not in normal cells. Similarly, our data are consistent with the observation that dantrolene had no effect on single RyR2 channel currents in lipid bilayer experiments using SR microsomes isolated from normal rabbit hearts (12) , presumably because these channels are from nondiseased animals and have stable interdomain interactions.
HF myocytes had a lower threshold for arrhythmogenic Ca 2ϩ waves, i.e., the [Ca 2ϩ ] SR at which Ca 2ϩ waves are initiated are lower in HF myocytes compared with cells from normal hearts. This again implicates RyR dysfunction in this model of HF, where NCX upregulation (together with additional changes in Ca 2ϩ signaling and E-C coupling) has been shown to lead to Ca 2ϩ -dependent delayed afterdepolarizations and functionally results in an increased propensity for arrhythmogenic Ca 2ϩ waves despite a decrease in SR Ca 2ϩ load (36 -38) . The effect that HF has on the wave threshold is still a topic of debate. It has been shown that HF myocytes have an unchanged wave threshold (38) and, conversely, that they have a decreased wave threshold (6) . The latter is consistent with our results. While dantrolene had no effects on the Ca 2ϩ wave threshold in normal myocytes, it significantly increased the threshold in HF myocytes and therefore exerts a profound antiarrhythmic effect on cellular Ca 2ϩ cycling. Dantrolene has also been shown to have beneficial effects in a transgenic mouse model of catecholaminergic polymorphic ventricular tachycardia (CPVT), an inherited arrhythmogenic disease associated with RyR2 mutations where destabilized or unzipped RyR2s cause disturbances of cardiac rhythm and sudden cardiac death. It has been shown that in CPVT, the affinity of calmodulin binding to RyR2 is reduced upon posttranslational modification by PKA phosphorylation (49) . This seems to destabilize the channel and be a critical cause of the spontaneous local Ca 2ϩ -release events characterizing CPVT, which can be prevented by treatment with dantrolene (49) . Furthermore, in a human CPVT mouse model, dantrolene prevented CPVT, presumably by inhibiting Ca 2ϩ leak through RyR2, providing an in vivo antiarrhythmic effect of dantrolene (25) .
In our study, dantrolene corrected two key adverse effects of Ca 2ϩ handling in HF: it decreased SR Ca 2ϩ leak (Ca 2ϩ sparks), thus increasing SR Ca 2ϩ load, and it reduced the propensity of proarrhythmic Ca 2ϩ -release events (Ca 2ϩ sparks and Ca 2ϩ waves) despite the increase in load. This is the first study to directly measure SR Ca 2ϩ before and after dantrolene treatment in both normal and HF myocytes. In light of the observation that ϳ50% of HF patients die from arrhythmogenesis (22) , the finding that dantrolene reduces arrhythmogenicity without compromising inotropy makes dantrolene a potentially useful drug for the treatment of HF via its antiarrhythmic effects. Mechanistically, dantrolene can preserve inotropy while at the same time act as an antiarrhythmic agent, given that we have shown that it inhibits diastolic Ca 2ϩ release but not systolic release in HF cells. Our data show that the fractional release in HF myocytes is decreased by dantrolene due to a significant increase in the SR Ca 2ϩ content while not affecting transient amplitude, with the net effect being no change in inotropy. We showed that dantrolene inhibits RyRmediated leak in the form of Ca 2ϩ sparks, thus preventing the formation of an arrhythmogenic substrate in HF myocytes (4) . It was interesting that in our rabbit HF model, we did not see significant inotropic effects during pacing-induced Ca 2ϩ transients, an effect that was observed in a study in canine ventricular myocytes (24) . However, in support of our data, a similar result as presented here with dantrolene (decreased diastolic release without compromising inotropy) was shown with tetracaine inhibition of RyR activity in rat ventricular myocytes challenged with isoproterenol (45) . Furthermore, as dantrolene produces a strong inhibition of diastolic Ca 2ϩ -release events, this raises the possibility that dantrolene could be used in conjunction with positive inotropic agents that normally cause adverse effects due to the arrhythmogenesis associated with positive inotropy, increased SR Ca 2ϩ content, and arrhythmogenic diastolic Ca 2ϩ release. Therefore, in the failing heart, dantrolene can preserve inotropy while at the same time act as an antiarrhythmic agent.
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